| Name | Title | Contact Details |
|---|---|---|
Karl Hertz |
Chief Operating Officer | Profile |
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Established in January, 2000, following the consolidation of St. Elizabeth Hospital and Elizabeth General Medical Center, Trinitas Regional Medical Center is a full-service healthcare facility serving those who live and work in Eastern and Central Union County. Operating on two major campuses, Trinitas Regional Medical Center has 554 beds, including a 120-bed long-term care center. Trinitas Regional Medical Center is proud to offer state-of-the-art medicine backed by compassion and competence. Our friendly, professional staff and skilled physicians are the foundation of the care we provide. Together, our medical team offers the community the most advanced technological care in every area of medicine and surgery. Utilizing a full spectrum of sophisticated inpatient, outpatient and long-term care services, Trinitas Regional Medical Center is proud to have forged a lifelong partnership with families, physicians and communities to provide the best care in a supportive and caring environment. We treat over 17,000 inpatients annually, 70,000 emergency patients, and several hundred thousand outpatients. Trinitas Regional Medical Center is pleased to offer a number of Centers of Excellence and specialized major services, including Behavioral Health,Bloodless Medicine, Cancer Care, Cardiology, Diabetes Management,Maternal and Child Health, Renal Services, School of Nursing, Senior Services, Sleep Disorders, Women`s Services, Wound Healing and more. A Catholic teaching hospital, Trinitas Regional Medical Center is sponsored by the Sisters of Charity of Saint Elizabeth in partnership with Elizabethtown Healthcare Foundation.
Whisper Hearing Center is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Dolomite Centre / Syrris / Blacktrace is a Charlestown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hale Ho Aloha Icf is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.